Biggest News Aggregation in the World
📰 Registration Document News

Page 46 - Registration Document News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Registration Document. Real-time updates on events, politics, business and more.

BUREAU VERITAS - Description of the share buyback program authorized by the Combined Shareholders' Meeting of Bureau Veritas SA of June 22, 2023

  Regulated information Description of the share buyback program authorized by the Combined Shareholders’ Meeting ofBureau Veritas SA of June 22, 2023 Pursuant to Articles 241-1...
Neuilly Sur Seine France General Bureau Veritas Combined Shareholder Meeting General Regulations Registration Document

CNN Anderson Cooper 360 June 4, 2024 04:45:00

>> cnn has exclusively obtained documents that suggests a top russian general, sergey surovikin, who has not been seen in public since last saturday short-lived or vault was a secret vip member of the mercenary wagner group that led the rebellion. cnns matthew chance joins us now from moscow for more on the man nicknamed general armageddon through his ruthless tactics. matthew, these documents, what do they tell us about general surovikin? >> they are pretty interesting. because they suggest or ...
Up Cnn General Surovikin Vip Member Matthew Chance Mercenary Wagner Registration Document

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Resu...
France General United States United Kingdom Nicolas Bogler Ipsen Euronext Jean Christophe Marcoux

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen (OTC:IPSEY)

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placeboElafibranor was well tolerated with a safety profile
United Kingdom France General United States Stephanie Boyer Amy Wolf Pascal Prigent

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science